Clinical Research Directory

Inclusion Criteria: * 18 years of age or older * An established diagnosis of Type 1 diabetes * Self-reported glycated hemoglobin (HbA1c) below 8% (64 mmol/mol) * Body Mass Index 18-40 kg/m2 * Fluent in written and spoken English * Own a personal iPhone 6s or later (iOS 15+ or newer) or Android smartphone (version 12 or newer) and willing to use this phone to download and use the app for the study * Own a personal Dexcom CGM and willing to provide the study researchers access to it's data during the study. * Willing to use the study wearable devices (Oura ring, Empatica wristband) * Resides in the San Francisco Bay area and willing to travel to Novato, CA on at least two occasions for the in person assessments at the Buck Institute. * If using long-acting insulin (e.g. Basaglar, Lantus, Levemir, Toujeo, Tresiba), must be on a dosing schedule that involves administration of insulin only at bedtime and no other times of day * Willing to stop use of prescription or over-the-counter medications containing acetaminophen (e.g. Tylenol, Percocet, Nyquil and other common medications for cold and flu, etc.) due to potential interference with the study-provided continuous glucose monitor. Exclusion Criteria: * Pregnant or breastfeeding * Current tobacco use * Allergy to dairy or soy * History of pancreatic disease (other than diabetes) or pancreatic transplantation * Active malignancy or chemotherapy for malignancy within the past year * History of bariatric surgery or other gastrointestinal surgery anticipated to affect glucose metabolism, or any cause of gastroparesis * Renal, hepatic, cardiovascular, or other systemic disease likely to interfere with glucose metabolism or study participation. * History of severe hypoglycemia or diabetes-related ketoacidosis in the prior 6 months or \>2 episodes in the past 12 months. * Overnight hospitalization for any reason in the past 3 months. * Current use of the following medications: Calcium channel blockers (e.g., verapamil), glucocorticoids, non-selective beta blockers (e.g., propranolol), GLP-1 receptor agonists, SGLT inhibitors, DPP-4 inhibitors, sulfonylureas, meglitinides, metformin, or thiazolidinediones.